Rigel Pharmaceuticals Reports Revenue Surge and Promising Clinical Trial Progress for R289

Rigel Pharmaceuticals Reports Strong Revenue Growth and Advances Clinical Trials

Rigel Pharmaceuticals, Inc., a biotechnology company specializing in hematologic disorders and cancer therapies, announces its preliminary fourth quarter 2025 total revenue of approximately $69.8 million, marking a significant increase from $57.6 million in the same quarter of the previous year. This growth is primarily driven by robust net product sales, which reach $65.4 million compared to $46.5 million in Q4 2024. The sales performance of Rigel’s key products showcases the company’s momentum in the market, with TAVALISSE® generating $45.6 million, GAVRETO® contributing $10.2 million, and REZLIDHIA® bringing in $9.6 million. Additionally, Rigel reports $4.4 million in contract revenues, underscoring the diverse revenue streams fueling its growth.

The company’s clinical pipeline remains a focal point, particularly with its ongoing Phase 1b study of R289 for lower-risk myelodysplastic syndromes (MDS). Early results indicate that R289 has been generally well tolerated among patients, with a promising 33% response rate in transfusion-dependent patients receiving a daily dose of 500 mg, and a 40% response rate in those treated with 500 mg twice daily. Rigel is on track to finalize enrollment in the dose expansion phase of this study, with plans to recommend a Phase 2 dose by the second half of 2026. This commitment to advancing clinical development is pivotal for the company as it seeks to enhance its therapeutic offerings and address unmet medical needs in hematologic disorders.

Looking forward, Rigel Pharmaceuticals forecasts total revenue for the full year 2026 to be between $275 million and $290 million, with net product sales anticipated to be between $255 million and $265 million. CEO Raul Rodriguez emphasizes 2025 as a transformative year for Rigel, highlighting the company’s achievement of $77 million in cash generation. This financial stability positions Rigel favorably for continued commercial success and ongoing clinical development efforts in the coming year.

In summary, Rigel Pharmaceuticals’ recent revenue growth and ongoing clinical advancements reflect its strategic focus on delivering innovative therapies for hematologic disorders and cancer. The company’s strong product performance, coupled with promising clinical trial results for R289, paints a positive outlook as it prepares for future developments in 2026.